Core Insights - Upstream Bio, Inc. is set to report top-line results from the Phase 2 VALIANT trial of verekitug, a treatment targeting the TSLP receptor, on February 11, 2026 [1][2] Group 1: Company Overview - Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [4] - The company is advancing verekitug, the only known antagonist in clinical development targeting the TSLP receptor, which is involved in inflammatory responses [4] - Upstream Bio aims to address significant unmet needs in patients underserved by current standard care through its development of verekitug [4] Group 2: VALIANT Trial Details - The VALIANT trial is a Phase 2 global, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of verekitug in 478 patients with severe asthma [2] - Participants in the trial were divided into four groups, receiving either 100 mg or 400 mg of verekitug every 24 weeks, 100 mg every 12 weeks, or a placebo, administered subcutaneously [2]
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma